截至发稿，华北制药市值为102亿元。 每经头条（nbdtoutiao）——与美元脱钩后，暴涨102倍，揭秘黄金疯涨背后神秘的"无形之手"！专家： 推动金价上涨的逻辑没有变 （记者 曾健辉） 每经AI快讯，华北制药（SH 600812，收盘价：5.94元）10月9日晚间发布公告称，截至本公告披露日， 公司及控股子公司对外担保总额约为17.01亿元，占2024年度经审计归属于上市公司普通股股东净资产 的31.56%，其中公司为控股子公司提供担保总额约为16.11亿元，占2024年度经审计归属于上市公司普 通股股东净资产的29.89%；对合并报表外单位担保金额为9000万元，占2024年度经审计归属于上市公 司普通股股东净资产的1.67%。 2025年1至6月份，华北制药的营业收入构成为：化学制剂药占比42.67%，化学原料药占比25.02%，生 物制剂占比16.71%，医药及其它物流贸易占比6.76%，医药中间体占比6.47%。 ...

Group 1 - The company Tian Shi Li announced on September 17 that it will hold the 14th meeting of the 9th Board of Directors on September 17, 2025, to approve the proposal to use idle funds to purchase bank wealth management products, with a maximum investment of 3 billion RMB [1] - The funds can be used on a rolling basis within the approved limit, and the transaction amount at any point during the investment period, including reinvested earnings, shall not exceed 3 billion RMB [1] - As of the report date, the market capitalization of Tian Shi Li is 23.8 billion RMB [1] Group 2 - For the fiscal year 2024, the revenue composition of Tian Shi Li is as follows: Traditional Chinese medicine accounts for 70.89%, chemical preparations 15.38%, pharmaceutical commerce 10.53%, biological drugs 2.25%, and chemical raw materials 0.61% [1]

Group 1 - The total external guarantees provided by the company and its subsidiaries amount to approximately 1.656 billion yuan, which represents 30.72% of the audited net assets attributable to ordinary shareholders for the year 2024 [1] - The company has provided guarantees totaling about 1.566 billion yuan for its subsidiaries, accounting for 29.05% of the audited net assets attributable to ordinary shareholders for 2024 [1] - The amount of guarantees for entities outside the consolidated financial statements is 90 million yuan, which is 1.67% of the audited net assets attributable to ordinary shareholders for 2024 [1] Group 2 - For the first half of 2025, the revenue composition of the company is as follows: chemical preparations account for 42.67%, chemical raw materials account for 25.02%, biological preparations account for 16.71%, pharmaceutical and other logistics trade account for 6.76%, and pharmaceutical intermediates account for 6.47% [1] - The current market capitalization of the company is 10.7 billion yuan [1]

Group 1 - The stock price of Te Yi Pharmaceutical reached 9.28 yuan as of the close on August 15, 2025, with an increase of 0.10 yuan, representing a rise of 1.09% [1] - The trading volume on that day was 153,060 hands, with a transaction amount of 1.41 billion yuan [1] - Te Yi Pharmaceutical operates in the pharmaceutical manufacturing industry, primarily engaged in the research, production, and sales of traditional Chinese medicine, chemical preparations, chemical raw materials, and chemical products [1] Group 2 - In the revenue composition for 2024, the pharmaceutical industry accounted for 97.65% of the company's total revenue [1] - On the evening of August 15, Te Yi Pharmaceutical announced that its sixth board of directors' second meeting approved a proposal to use part of the idle raised funds from the 2023 fiscal year for cash management and to temporarily supplement working capital [1]

Group 1 - Tianjin Tasly Pharmaceutical announced the convening of its 12th meeting of the 9th Board of Directors on August 14, 2025, to review the "2025 Semi-Annual Report" and other documents [1] - For the year 2024, the revenue composition of Tasly is as follows: Traditional Chinese Medicine accounts for 70.89%, Chemical Preparations 15.38%, Pharmaceutical Commerce 10.53%, Biological Drugs 2.25%, and Chemical Raw Materials 0.61% [1] - As of the report date, Tasly's market capitalization is 24.2 billion yuan [1] Group 2 - Huakang Co., Ltd. is facing uncertainty regarding an 11 billion yuan acquisition, as the major client of the acquisition target has been in debt crisis for two years, raising questions about its ability to contribute significant revenue [1]

Group 1 - The revenue composition of North China Pharmaceutical for the year 2024 is as follows: chemical preparations account for 44.02%, chemical raw materials account for 26.72%, biological preparations account for 16.36%, pharmaceutical intermediates account for 6.23%, and pharmaceutical and other logistics trade account for 4.61% [1] Group 2 - As of the announcement date, the total external guarantees provided by North China Pharmaceutical and its subsidiaries amount to approximately 1.757 billion yuan, which represents 32.6% of the audited net assets attributable to ordinary shareholders for the year 2024 [3] - The company has provided guarantees totaling approximately 1.667 billion yuan for its subsidiaries, accounting for 30.93% of the audited net assets attributable to ordinary shareholders for the year 2024 [3] - The amount of guarantees provided to entities outside the consolidated financial statements is 90 million yuan, which is 1.67% of the audited net assets attributable to ordinary shareholders for the year 2024 [3]

每经头条（nbdtoutiao）——"我们也深陷残酷价格战"！德资巨头中国区高管警告：智驾绝不能免费， 否则会给全行业带来灾难 （记者 王可然） 每经AI快讯，天士力（SH 600535，最新价：16.44元）8月1日晚间发布公告称，公司董事会于2025年8 月1日收到高级管理人员李江山先生提交的辞职报告。李江山先生由于工作变动原因，提请辞去公司副 总经理职务。根据《公司章程》及有关规定，李江山先生的辞职申请自辞职报告送达公司董事会时生 效。 2024年1至12月份，天士力的营业收入构成为：中药占比70.89%，化学制剂药占比15.38%，医药商业占 比10.53%，生物药占比2.25%，化学原料药占比0.61%。 ...

关于公司 2025 年第一季度主要经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 根据上海证券交易所《上市公司行业信息披露指引第六号——医药制造》及《关 于做好主板上市公司 2025 年第一季度报告披露工作的重要提醒》的要求，现将公 司 2025 年第一季度主要经营数据披露如下： 一、报告期内分行业经营数据 证券代码：600535 证券简称：天士力 编号：临 2025-040 号 天士力医药集团股份有限公司 1 单位：元 币种：人民币 行业 主营业务收入 主营业务成本 毛利率（%） 2025 年 1 季度 2024 年 1 季度 增长 率（%） 2025 年 1 季度 2024 年 1 季度 增长 率（%） 2025 年 1 季度 2024 年 1 季度 增长 率 医药 工业 1,841,853,945.50 1,808,711,593.51 1.83 544,797,151.33 507,143,805.22 7.42 70.42 71.96 -1.54 医药 商业 201,533,271.02 226 ...